Cornish businessman scoops Topra award
Jonathan Trethowan wins Inspiration category
A panel of five judges awarded Trethowan the honour at the awards, which recognise excellence within the industry, after he was nominated by Trac’s regulatory affairs executive, Lisa Pascoe.
Trethowan set up the company with his wife Sarah in 2001 and has seen it grow to work with UK and European pharmaceutical companies, ensuring that they are in compliance with the latest regulations concerned with the manufacture and marketing of medicines.
‘I am absolutely delighted to have won the Inspiration Award – it is a fantastic honour and to be honest I was thrilled just to be nominated,’ said Trethowan.
Pascoe added: ‘Over the past five years Jonathan has developed an excellent in-house training programme that has helped coach and support myself and six other graduates to become experienced regulatory professionals in our own right.
‘In addition, he also participates in a TOPRA working party that is identifying future approaches to professional development; I think his involvement at TRAC and within the industry as a whole shows his passion and commitment.’
You may also like
Regulatory
Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV
Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Regulatory
Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes
Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes
Regulatory
Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court
The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign drugmakers operating in the Chinese market